Theoretical risks are extrapolated from IGF-1 biology: Hypoglycemia : IGF-1 shares structural homology with insulin and can activate insulin receptors, particularly at high concentrations Growth factor signaling : Sustained IGF-1R activation carries theoretical oncogenic potential, as the IGF-1 axis promotes cell proliferation and survival Systemic effects : Reduced IGFBP binding means greater systemic exposure to active growth factor, potentially amplifying both therapeutic and adverse effects Organ-specific : Potential for cardiac hypertrophy and other tissue growth with chronic exposure MGF Side Effects# MGF safety data are limited to preclinical observations: Rapid clearance : The very short half-life limits systemic exposure, which may reduce off-target effects Local action : Endogenous MGF acts primarily as a local paracrine factor, suggesting that targeted administration may have a favorable safety profile No human data : Without clinical trials, the safety profile in humans remains undefined Proliferative concerns : As a satellite cell activator, theoretical concerns exist regarding uncontrolled proliferation, though preclinical data have not demonstrated this Dosing and Administration Comparison# IGF-1 LR3 Dosing# MGF Dosing# The short half-life of native MGF is a significant practical limitation
Rybelsus (semaglutide) Rybelsus (semaglutide) is an oral medication that helps patients with type 2 diabetes manage their blood glucose levels
Overall lighter, brighter skin tone
Naderi A, de Oliveira EP, Ziegenfuss TN, Willems MT
an FDA advisory committee rejected adding it to the approved compounding list in 2024, citing toxicity and an unresolved cardiac signal
Remember, this is not a one-size-fits-all solution
